Reversal of profound paralysis: use of large doses of edrophonium to antagonize vecuronium and pancuronium induced neuromuscular blockade.
The ability to evoke reversal of dense vecuronium- and pancuronium-induced paralysis (T1 10% of control) with edrophonium 1.0 mg.kg-1 was studied using train-of-four nerve stimulation and electromyographic monitoring. Two different end-points, train-of-four ratios of 0.5 and 0.7, were used to define "adequate reversal", and the results for both relaxants were compared. Reversal was reliable and rapid for vecuronium if either ratio was used with times of 2.8 (1.5) and 9 (3) min required to achieve ratios of 0.5 and 0.7, respectively. However, if the block was due to pancuronium, reversal was unreliable with 2 of 9 and 4 of 9 patients not achieving ratios of 0.5 and 0.7, respectively. Reversal was also markedly prolonged in this group with a mean time of 37 (23) min to achieve a ratio of 0.7, and in almost half these patients a supplementary dose of edrophonium was required.
Power
S J
SJ
Department of Anaesthetics, United Medical School, Guy's Hospital, London, England, UK.
Jones
R M
RM
D000293:Adolescent; D000328:Adult; D000368:Aged; D004491:Edrophonium / Q000008:administration & dosage / Q000627:therapeutic use*; D004558:Electric Stimulation; D004576:Electromyography; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009469:Neuromuscular Junction / Q000187:drug effects; D010197:Pancuronium / Q000037:antagonists & inhibitors*; D013997:Time Factors; D014459:Ulnar Nerve / Q000187:drug effects / Q000502:physiology; D014673:Vecuronium Bromide / Q000037:antagonists & inhibitors*
D004491:Edrophonium; D014673:Vecuronium Bromide; D010197:Pancuronium